600833.SS(600833.SS)

$11.70—

Chart

600833.SS(600833.SS)

SHH

$11.70—

Chart Studio

600833.SS(600833.SS)

600833.SS

Overview Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

8/14/26

SHANGHAI NO.1 PHARMACY (600833.SS)

Friday

6:40 AM

Thesis: The significant drop in net income and ongoing regulatory pressures are raising concerns about the company's profitability and operational efficiency.

Revenue Outlook

Metric	FY2024	FY2025
Revenue	$1.9B	$2.1B
Rev. Growth	+5.3%	+11.2%
EPS	$0.73	$0.26
EPS Growth	+82.5%	-64.4%
P/E	16.0×	45.0×

What Could Go Wrong

1Decline in net income by 64.6% raises concerns about operational efficiency and cost management.
2Increased regulatory scrutiny on drug pricing may lead to tighter margins across the industry.
3Regulatory changes in the pharmaceutical industry could impact pricing and profitability
4Technological disruption in healthcare delivery, such as telemedicine, could affect traditional pharmacy sales
5Increased competition from e-pharmacies and online health platforms
6Market entry of larger pharmacy chains with greater resources
7Low liquidity risk due to a healthy current ratio of 1.69
8Potential vulnerability to cash flow fluctuations given the significant decline in net income

FY2025 Snapshot

Revenue: $2.1B
Rev. Growth: +11.2%
Gross Margin: 16.0%
Op. Margin: 3.5%
Net Margin: 2.7%
Net Income: $58M
NI Growth: -64.6%
EPS: $0.26
1Y Return: -8.9%

600833.SS Chart

My Notes

"Management has acknowledged the challenges in maintaining margins amidst increasing competition and regulatory scrutiny."
Moat: The company has a moderate moat due to its established brand and distribution network, but faces increasing competition.
Watch: The rise of e-pharmacies poses a significant threat to traditional retail pharmacy models.
value - the company's low price-to-sales ratio indicates potential undervaluation relative to its peers.
Minimal impact from interest rates, as the company is not heavily reliant on debt financing and consumer demand for healthcare is relatively…
Watch on earnings: Same-store sales growth rate, Gross margin percentage, Regulatory changes in healthcare policy.

One Sentence Summary:

The bear case: decline in net income by 64.6% raises concerns about operational efficiency and cost management.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Writing up the research note…

First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Metric

FY2024

FY2025

P/E

16.0×

45.0×

What Could Go Wrong

1Decline in net income by 64.6% raises concerns about operational efficiency and cost management.

2Increased regulatory scrutiny on drug pricing may lead to tighter margins across the industry.

3Regulatory changes in the pharmaceutical industry could impact pricing and profitability

4Technological disruption in healthcare delivery, such as telemedicine, could affect traditional pharmacy sales

5Increased competition from e-pharmacies and online health platforms

6Market entry of larger pharmacy chains with greater resources

7Low liquidity risk due to a healthy current ratio of 1.69

8Potential vulnerability to cash flow fluctuations given the significant decline in net income

My Notes

"Management has acknowledged the challenges in maintaining margins amidst increasing competition and regulatory scrutiny."

Moat: The company has a moderate moat due to its established brand and distribution network, but faces increasing competition.

Watch: The rise of e-pharmacies poses a significant threat to traditional retail pharmacy models.

value - the company's low price-to-sales ratio indicates potential undervaluation relative to its peers.

Minimal impact from interest rates, as the company is not heavily reliant on debt financing and consumer demand for healthcare is relatively…

Watch on earnings: Same-store sales growth rate, Gross margin percentage, Regulatory changes in healthcare policy.